Eisai US
Eisai US, operating as Eisai Inc., is the U.S. subsidiary of Eisai Co., Ltd., a global pharmaceutical company based in Japan. Established in 1995, with earlier activities dating back to 1987, Eisai US is headquartered in New Jersey. The company focuses on neurology and oncology, developing innovative therapies to address unmet medical needs. Eisai US specializes in research and development in neuroscience, particularly for Alzheimer’s disease, and oncology, including treatments for brain tumors and ovarian cancer. The company manages over 30 clinical trials globally and collaborates with major partners like Pfizer and Johnson & Johnson for drug development and distribution. Its product portfolio includes FDA-approved medications such as Aricept for Alzheimer’s, Leqembi for early Alzheimer’s, and Gliadel Wafer for brain tumors. Eisai US emphasizes its "human health care" philosophy, aiming to benefit patients and their families through its initiatives.
Work at Eisai US in HR or recruiting? Claim this page
Headcount trend
Eisai US went from 1,761 employees in Jul 2023 to 1,792 in Jun 2025. Last 6 months: 34 people joined, 66 left.
Org structure
Headcount by department
H-1B sponsorship
The department split adds up all the years listed above. FY2026 alone: 11 filings.
Peer reviews
Worked with someone at Eisai US?
Anonymous peer reviews on OffTheRecord
Similar companies
Eisai US FAQ
How many employees does Eisai US have?
Eisai US has about 1,792 employees, down 0.5% over the last 3 months (as of Jun 2025).
Does Eisai US sponsor H1B visas?
Yes. Eisai US filed 11 H1B (LCA) applications in FY2026, according to the latest U.S. Department of Labor disclosures. Most of them were for Engineering roles.
What is Eisai US's revenue per employee?
Eisai US makes about $2.94M in revenue per employee, based on $5.27B annual revenue and 1,792 employees.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles. Updated 21 Oct 2026.
